Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Adage Capital Management Reiterates Stake in CARDIOME PHARMA CORP (CRME)

In its latest filing, Adage Capital Management, managed by Phill Gross and Robert Atchinson, has reported ownership of 1.33 million shares of CARDIOME PHARMA CORP (NASDAQ:CRME). The stake amasses 8.9% of the company’s common shares, and is unchanged from the end of the third quarter of 2013.

Phill Gross Adage Capital Management

CARDIOME PHARMA CORP (NASDAQ:CRME) is a specialty pharmaceutical company dedicated to the development and commercialization of cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease.

Jim Simons’s Renaissance Technologies owned 210,113 shares of CARDIOME PHARMA CORP (NASDAQ:CRME) at the end of third quarter of 2013. Ken Griffin’s Citadel Investment Group held 10,782 shares of the company by the end of third quarter.

In late November 2013, Fortress Investment Group, managed by Michael Novogratz, reported adding CARDIOME PHARMA CORP (NASDAQ:CRME) to its equity portfolio, in a new filing with the Securities and Exchange Commission. Fortress disclosed a passive stake, which amasses 2.5 million shares, with an aggregate value of $15.4 million at the current share price of the company.

The largest stake in Adage Capital equity portfolio is represented by Apple Inc. (NASDAQ:AAPL), in which Adage Capital disclosed 1.38 million shares worth about $657.41 million.

Adage Capital was founded by Phil Gross and Robert Atchinson in 2001. Gross was initially a healthcare and retail analyst at the Harvard Management Company (HMC). Later, he became a partner at the company, where he spent 18 years.

In December, Adage Capital reported raising its exposure to Heartware International Inc. (NASDAQ:HTWR) to 836,190 shares, from 688,952 shares held at the end of September, as revealed in the fund’s latest 13G. Adage Capital Management disclosed ownership of 5.07% of the company’s common stock.

Disclosure: none

Recommended Reading:

Deerfield Management Further Raises Its Position in Auspex Pharmaceuticals Inc (ASPX)

Iroquois Capital Edges up Stake in National Holdings Corporation (NHLD)

Cannell Capital Boosts its Stake in ZipRealty, Inc. (ZIPR)

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!